The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Abstract
BACKGROUND Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. METHODS In this single-arm, open-label, phase 2 basket trial, we recruited patients from 26 hospitals in six European countries and the USA. Adults (aged ≥18 years) with a pathologically proven diagnosis of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease as per Response Criteria in Solid Tumors (RECIST) version 1.1, absence of brain metastasis, adequate organ function, and pre-treated with only one previous chemotherapy-containing line of treatment (minimum 3 weeks before study initiation) were eligible. Treatment consisted of 3·2 mg/m2 lurbinectedin administered as a 1-h intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. The primary outcome was the proportion of patients with an overall response (complete or partial response) as assessed by the investigators according to RECIST 1.1. All treated patients were analysed for activity and safety. This study is ongoing and is registered with ClinicalTrials.gov, NCT02454972. FINDINGS Between Oct 16, 2015, and Jan 15, 2019, 105 patients were enrolled and treated with lurbinectedin. Median follow-up was 17·1 months (IQR 6·5-25·3). Overall response by investigator assessment was seen in 37 patients (35·2%; 95% CI 26·2-45·2). The most common grade 3-4 adverse events (irrespective of causality) were haematological abnormalities-namely, anaemia (in nine [9%] patients), leucopenia (30 [29%]), neutropenia (48 [46%]), and thrombocytopenia (seven [7%]). Serious treatment-related adverse events occurred in 11 (10%) patients, of which neutropenia and febrile neutropenia were the most common (five [5%] patients for each). No treatment-related deaths were reported. INTERPRETATION Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile. Lurbinectedin could represent a potential new treatment for patients with SCLC, who have few options especially in the event of a relapse, and is being investigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial. FUNDING Pharma Mar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 904
O'Brien, M. E. R., Ciuleanu, T.-E., Tsekov, H., Shparyk, Y., Čučeviá, B., Juhasz, G., Thatcher, N., Ross, G. A., Dane, G. C., & Crofts, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5821 · Cited by 649
Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., & Felip, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt178 · Cited by 613
Self-citationTargeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
Eckardt, J. R., von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Preston, A. J., Dane, G., & Ross, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3998 · Cited by 393
von Pawel, J., Jotte, R., Spigel, D. R., O'Brien, M. E. R., Socinski, M. A., Mezger, J., Steins, M., Bosquée, L., Bubis, J., Nackaerts, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5392 · Cited by 352
Self-citation
Cited by
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0058 · Cited by 486
Self-citationFan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.002 · Cited by 135
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03600-2 · Cited by 122
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Metadata
- Authors
- Trigo, J., Subbiah, V., Besse, B., Moreno, V., López, R., Sala, M. A., Peters, S., Ponce, S., Fernández, C., Alfaro, V., Gómez, J., Kahatt, C., Zeaiter, A., Zaman, K., Boni, V., Arrondeau, J., Martínez, M., Delord, J.-P., Awada, A., Kristeleit, R., Olmedo, M. E., Wannesson, L., Valdivia, J., Rubio, M. J., Anton, A., Sarantopoulos, J., Chawla, S. P., Mosquera-Martinez, J., D'Arcangelo, M., Santoro, A., Villalobos, V. M., Sands, J., & Paz-Ares, L.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 21
- Issue
- 5
- Pages
- 645-654
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3013383466
- Cited by
- 486
- References
- 21
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30068-1
- The paper
- Trigo, J., Subbiah, V., Besse, B., Moreno, V., López, R., Sala, M. A., Peters, S., Ponce, S., Fernández, C., Alfaro, V., Gómez, J., Kahatt, C., Zeaiter, A., Zaman, K., Boni, V., Arrondeau, J., Martínez, M., Delord, J.-P., Awada, A., . . . Paz-Ares, L. (2020). Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30068-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
